Q1 EPS Estimate for Nektar Therapeutics Increased by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at William Blair lifted their Q1 2025 earnings estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their previous forecast of ($0.22). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. William Blair also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.88) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.33. The business had revenue of $29.18 million for the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.

NKTR has been the topic of several other reports. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price target on the stock. Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a report on Friday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a report on Thursday, March 13th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $4.92.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $0.88 on Monday. The firm has a market capitalization of $162.36 million, a price-to-earnings ratio of -1.05 and a beta of 0.65. The company’s fifty day moving average is $0.87 and its two-hundred day moving average is $1.07. Nektar Therapeutics has a 52-week low of $0.65 and a 52-week high of $1.93.

Insider Transactions at Nektar Therapeutics

In related news, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the transaction, the insider now owns 351,892 shares in the company, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the transaction, the insider now owns 326,904 shares of the company’s stock, valued at approximately $307,289.76. This represents a 13.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 118,591 shares of company stock worth $112,525 in the last quarter. 3.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Eventide Asset Management LLC lifted its stake in Nektar Therapeutics by 24.8% in the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after buying an additional 1,870,904 shares in the last quarter. Nantahala Capital Management LLC lifted its position in shares of Nektar Therapeutics by 90.0% in the fourth quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock worth $7,263,000 after purchasing an additional 3,700,000 shares in the last quarter. Woodline Partners LP lifted its position in shares of Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after purchasing an additional 3,242,841 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Nektar Therapeutics by 17.5% in the fourth quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company’s stock worth $3,637,000 after purchasing an additional 583,153 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Nektar Therapeutics by 11.9% in the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after purchasing an additional 355,759 shares in the last quarter. Institutional investors own 75.88% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.